AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife [Yahoo! Finance]
AngioDynamics, Inc. (NASDAQ: ANGO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength? [Yahoo! Finance]
NanoKnife gains FDA clearance for prostate tissue ablation [Yahoo! Finance]